[Yahong Pharmaceutical: APL-2501 has completed the enrollment of the first subject in the Phase I clinical trial] On September 22, Yahong Pharmaceutical (688176.SH) announced that the company's independently developed APL-2501 has completed the enrollment of the first subject in the Phase I/II clinical trial in patients with advanced solid tumors. The drug is an anti-CLDN6/9 antibody-drug conjugate independently developed by the company based on a topoisomerase inhibitor. It can be used to treat a variety of advanced solid tumors such as ovarian cancer, non-small cell lung cancer, endometrial cancer, and gastric cancer. The research has been approved by the US FDA and the State Food and Drug Administration, and this matter will not have a significant impact on the company's recent performance.